SE0203349D0 - New use - Google Patents

New use

Info

Publication number
SE0203349D0
SE0203349D0 SE0203349A SE0203349A SE0203349D0 SE 0203349 D0 SE0203349 D0 SE 0203349D0 SE 0203349 A SE0203349 A SE 0203349A SE 0203349 A SE0203349 A SE 0203349A SE 0203349 D0 SE0203349 D0 SE 0203349D0
Authority
SE
Sweden
Prior art keywords
formulation
thromboembolism
sub
treatment
new use
Prior art date
Application number
SE0203349A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Edman
Karin Wingstrand
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203349A priority Critical patent/SE0203349D0/xx
Publication of SE0203349D0 publication Critical patent/SE0203349D0/xx
Priority to JP2004551332A priority patent/JP2006507323A/ja
Priority to AU2003276801A priority patent/AU2003276801A1/en
Priority to CNA2003801030983A priority patent/CN1711104A/zh
Priority to EP03811169A priority patent/EP1581255A1/en
Priority to PCT/SE2003/001738 priority patent/WO2004043486A1/en
Priority to BR0316123-4A priority patent/BR0316123A/pt
Priority to US10/533,869 priority patent/US20060014699A1/en
Priority to MXPA05005118A priority patent/MXPA05005118A/es
Priority to KR1020057008436A priority patent/KR20050074598A/ko
Priority to CA002504480A priority patent/CA2504480A1/en
Priority to ZA200503711A priority patent/ZA200503711B/en
Priority to NO20052313A priority patent/NO20052313L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE0203349A 2002-11-12 2002-11-12 New use SE0203349D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0203349A SE0203349D0 (sv) 2002-11-12 2002-11-12 New use
CA002504480A CA2504480A1 (en) 2002-11-12 2003-11-11 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
EP03811169A EP1581255A1 (en) 2002-11-12 2003-11-11 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
AU2003276801A AU2003276801A1 (en) 2002-11-12 2003-11-11 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
CNA2003801030983A CN1711104A (zh) 2002-11-12 2003-11-11 一种含有凝血酶抑制剂美拉加群的水性药物制剂,及该制剂在制备通过鼻内给药治疗血栓栓塞的药物中的用途
JP2004551332A JP2006507323A (ja) 2002-11-12 2003-11-11 トロンビン阻害剤メラガトランを含む水性医薬製剤、および血栓塞栓症の処置において経鼻投与に使用するための医薬の製造における該製剤の使用。
PCT/SE2003/001738 WO2004043486A1 (en) 2002-11-12 2003-11-11 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
BR0316123-4A BR0316123A (pt) 2002-11-12 2003-11-11 Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico
US10/533,869 US20060014699A1 (en) 2002-11-12 2003-11-11 Aqueous pharmaceutical formulaton comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
MXPA05005118A MXPA05005118A (es) 2002-11-12 2003-11-11 Una formulacion farmaceutica acuosa que comprende el inhibidor de trombina, melagatran, y el uso de la formulacion en la fabricacion de un medicamento para utilizarse a traves de adminitracion nasal en el tratamiento de tromboembolismo.
KR1020057008436A KR20050074598A (ko) 2002-11-12 2003-11-11 트롬빈 억제제 멜라가트란을 포함하는 수성 약학 제제 및혈전색전증 치료에서 비강 투여에 의하여 사용하는 약제의제조에서의 상기 제제의 용도
ZA200503711A ZA200503711B (en) 2002-11-12 2005-05-09 An aqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture for use by nasal administration in treating thromboembolism
NO20052313A NO20052313L (no) 2002-11-12 2005-05-11 Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203349A SE0203349D0 (sv) 2002-11-12 2002-11-12 New use

Publications (1)

Publication Number Publication Date
SE0203349D0 true SE0203349D0 (sv) 2002-11-12

Family

ID=20289548

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203349A SE0203349D0 (sv) 2002-11-12 2002-11-12 New use

Country Status (13)

Country Link
US (1) US20060014699A1 (xx)
EP (1) EP1581255A1 (xx)
JP (1) JP2006507323A (xx)
KR (1) KR20050074598A (xx)
CN (1) CN1711104A (xx)
AU (1) AU2003276801A1 (xx)
BR (1) BR0316123A (xx)
CA (1) CA2504480A1 (xx)
MX (1) MXPA05005118A (xx)
NO (1) NO20052313L (xx)
SE (1) SE0203349D0 (xx)
WO (1) WO2004043486A1 (xx)
ZA (1) ZA200503711B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153946A1 (en) * 2003-12-24 2005-07-14 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
US7345093B2 (en) * 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP2480208A1 (en) 2009-09-23 2012-08-01 Indu Javeri Methods for the preparation of liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
SE9602145D0 (sv) * 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9900070D0 (sv) * 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy

Also Published As

Publication number Publication date
MXPA05005118A (es) 2005-07-01
WO2004043486A1 (en) 2004-05-27
US20060014699A1 (en) 2006-01-19
CN1711104A (zh) 2005-12-21
JP2006507323A (ja) 2006-03-02
AU2003276801A1 (en) 2004-06-03
WO2004043486A8 (en) 2005-03-17
ZA200503711B (en) 2006-11-29
KR20050074598A (ko) 2005-07-18
NO20052313L (no) 2005-06-06
CA2504480A1 (en) 2004-05-27
EP1581255A1 (en) 2005-10-05
BR0316123A (pt) 2005-09-27

Similar Documents

Publication Publication Date Title
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0209468A (pt) Composto ou sais ou solvatos deste farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada pelo hppar
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
NO20060974L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
SE0101932D0 (sv) Pharmaceutical combinations
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
EA200501105A1 (ru) Фармацевтическая композиция
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
ATE451934T1 (de) Pharmazeutische zusammensetzung zur behandlung von rhinitiden
HUP0204520A2 (en) Pharmaceutical composition containing esmolol and process for its preparation
NO20013301D0 (no) Ny dialysemetode
NO20052313L (no) Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates